Does RIMABOTULINUMTOXINB Cause Product use in unapproved indication? 32 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 32 reports of Product use in unapproved indication have been filed in association with RIMABOTULINUMTOXINB (Myobloc). This represents 18.2% of all adverse event reports for RIMABOTULINUMTOXINB.
32
Reports of Product use in unapproved indication with RIMABOTULINUMTOXINB
18.2%
of all RIMABOTULINUMTOXINB reports
0
Deaths
8
Hospitalizations
How Dangerous Is Product use in unapproved indication From RIMABOTULINUMTOXINB?
Of the 32 reports, 8 (25.0%) required hospitalization.
Is Product use in unapproved indication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIMABOTULINUMTOXINB. However, 32 reports have been filed with the FAERS database.
What Other Side Effects Does RIMABOTULINUMTOXINB Cause?
Death (34)
Dysphagia (17)
Dry mouth (15)
Off label use (15)
Drug ineffective (14)
Atypical mycobacterial infection (11)
Headache (10)
Nausea (9)
Asthenia (7)
Dizziness (7)
What Other Drugs Cause Product use in unapproved indication?
DUPILUMAB (33,452)
DICLOFENAC (12,197)
METHOTREXATE (8,930)
PREDNISONE (7,625)
RITUXIMAB (7,519)
MYCOPHENOLATE MOFETIL (5,910)
ACETAMINOPHEN (5,819)
CYCLOPHOSPHAMIDE (5,750)
RISPERIDONE (5,551)
TACROLIMUS (5,057)
Which RIMABOTULINUMTOXINB Alternatives Have Lower Product use in unapproved indication Risk?
RIMABOTULINUMTOXINB vs RIMEGEPANT
RIMABOTULINUMTOXINB vs RIOCIGUAT
RIMABOTULINUMTOXINB vs RIPRETINIB
RIMABOTULINUMTOXINB vs RISANKIZUMAB
RIMABOTULINUMTOXINB vs RISANKIZUMAB-RZAA